Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 5/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770189 | 0.84 | GLRA3 (0.34) | NR1D1ALDH1A1 | |
| SCHEMBL5004256 | 0.83 | GABRA5 (0.37) | NR1D1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL10367811 | 0.81 | NR1D1 (0.36) | NR1D1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL5007664 | 0.81 | NR1D1 (0.36) | NR1D1NR1H3GSTO1ALDH1A1GLA | |
| SCHEMBL10367552 | 0.80 | ACACB (0.37) | NR1D1GABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL18979341 | 0.77 | NR1D1 (0.35) | NR1D1NR1H3GSTO1 | |
| SCHEMBL17200937 | 0.77 | NR1D1 (0.35) | NR1D1NR1H3GSTO1 | |
| SCHEMBL15618181 | 0.76 | ACACB (0.35) | NR1D1GABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL17200916 | 0.76 | ACACB (0.35) | NR1D1GABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL26885902 | 0.76 | NR1D1 (0.33) | NR1D1NR1H3GSTO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305049-A1 | Mri Contrast Agents for Diagnosis and Prognosis of Tumors | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2008-12-11 | — | — | US | disclosed |
| EP-1848466-A2 | MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006080022-A2 | MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305049-A1 | Mri Contrast Agents for Diagnosis and Prognosis of Tumors | TFRC, FOLR1, CD14 | NR1D1 1804/4885GABRA1 122/4885GABRG2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.